{"title":"New era of nanoparticles facilitated co-delivery in cancer therapy: two heads are better than one","authors":"Sonam Grewal, Teenu Sharma, Rajan Swami","doi":"10.1007/s11051-023-05837-9","DOIUrl":null,"url":null,"abstract":"<div><p>Combinational chemotherapeutics gained attention in 1950s, when a sharp reduction in mortality of cancer patients was observed with simultaneous usage of selected anticancer drugs with diverse mechanisms of action. However, later toxicity concerns slowed their wider adoption. Hitches, like multidrug resistance further account for the inactivity of many of the anticancer drugs for numerous cancers, rang another alarm. In such situations, the treatment itself becomes a matter of concern for patients and clinicians. Nanotechnology emerged as a refuge to counter the threat of resistance and toxicities apprehension and at the same time elevates the efficacy as compared to non-nanotherapy counterparts. Subsequently, breakthroughs in biotherapeutics, theranostics, and targeting ligands changed the paradigm of nanoparticulate combinational therapy. Careful selection of drug cocktail into the single architecture of nanoparticles helps to co-deliver the drugs of different natures, to the same target simultaneously without any haywire distribution menace. With the everlasting necessity for nanotherapeutic co-delivery in cancer, it is of utmost importance to understand how far we have reached and why we are still lagging on the clinical front. The present review aims to bring updated information in the area of nanoparticle-based co-delivered therapeutics. Additionally, current progress and challenges have been reviewed in depth to present a holistic overview.</p><h3>Graphical Abstract</h3>\n <div><figure><div><div><picture><source><img></source></picture></div></div></figure></div>\n </div>","PeriodicalId":653,"journal":{"name":"Journal of Nanoparticle Research","volume":"25 9","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanoparticle Research","FirstCategoryId":"88","ListUrlMain":"https://link.springer.com/article/10.1007/s11051-023-05837-9","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Combinational chemotherapeutics gained attention in 1950s, when a sharp reduction in mortality of cancer patients was observed with simultaneous usage of selected anticancer drugs with diverse mechanisms of action. However, later toxicity concerns slowed their wider adoption. Hitches, like multidrug resistance further account for the inactivity of many of the anticancer drugs for numerous cancers, rang another alarm. In such situations, the treatment itself becomes a matter of concern for patients and clinicians. Nanotechnology emerged as a refuge to counter the threat of resistance and toxicities apprehension and at the same time elevates the efficacy as compared to non-nanotherapy counterparts. Subsequently, breakthroughs in biotherapeutics, theranostics, and targeting ligands changed the paradigm of nanoparticulate combinational therapy. Careful selection of drug cocktail into the single architecture of nanoparticles helps to co-deliver the drugs of different natures, to the same target simultaneously without any haywire distribution menace. With the everlasting necessity for nanotherapeutic co-delivery in cancer, it is of utmost importance to understand how far we have reached and why we are still lagging on the clinical front. The present review aims to bring updated information in the area of nanoparticle-based co-delivered therapeutics. Additionally, current progress and challenges have been reviewed in depth to present a holistic overview.
期刊介绍：
The objective of the Journal of Nanoparticle Research is to disseminate knowledge of the physical, chemical and biological phenomena and processes in structures that have at least one lengthscale ranging from molecular to approximately 100 nm (or submicron in some situations), and exhibit improved and novel properties that are a direct result of their small size.
Nanoparticle research is a key component of nanoscience, nanoengineering and nanotechnology.
The focus of the Journal is on the specific concepts, properties, phenomena, and processes related to particles, tubes, layers, macromolecules, clusters and other finite structures of the nanoscale size range. Synthesis, assembly, transport, reactivity, and stability of such structures are considered. Development of in-situ and ex-situ instrumentation for characterization of nanoparticles and their interfaces should be based on new principles for probing properties and phenomena not well understood at the nanometer scale. Modeling and simulation may include atom-based quantum mechanics; molecular dynamics; single-particle, multi-body and continuum based models; fractals; other methods suitable for modeling particle synthesis, assembling and interaction processes. Realization and application of systems, structures and devices with novel functions obtained via precursor nanoparticles is emphasized. Approaches may include gas-, liquid-, solid-, and vacuum-based processes, size reduction, chemical- and bio-self assembly. Contributions include utilization of nanoparticle systems for enhancing a phenomenon or process and particle assembling into hierarchical structures, as well as formulation and the administration of drugs. Synergistic approaches originating from different disciplines and technologies, and interaction between the research providers and users in this field, are encouraged.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
